| 000 | 01192 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250512040622.0 | ||
| 264 | 0 | _c19881123 | |
| 008 | 198811s 0 0 eng d | ||
| 022 | _a0077-0760 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTindall, R S | |
| 245 | 0 | 0 |
_aCiclosporin in the treatment of myasthenia gravis. _h[electronic resource] |
| 260 |
_bMonographs in allergy _c1988 |
||
| 300 |
_a135-47 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aCyclosporins _xadverse effects |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Evaluation |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKidney Diseases _xchemically induced |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMyasthenia Gravis _xdrug therapy |
| 650 | 0 | 4 | _aRandom Allocation |
| 650 | 0 | 4 | _aRisk Factors |
| 700 | 1 | _aPhillips, J T | |
| 700 | 1 | _aRollins, J A | |
| 700 | 1 | _aGreenlee, R G | |
| 700 | 1 | _aWells, L | |
| 700 | 1 | _aBelendiuk, G | |
| 773 | 0 |
_tMonographs in allergy _gvol. 25 _gp. 135-47 |
|
| 999 |
_c3179148 _d3179148 |
||